- Home
- ZCMD vs WINT Comparison
ZCMD vs WINT Comparison
Compare ZCMD & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCMD
- WINT
- Stock Information
- Founded
- ZCMD 2012
- WINT 1992
- Country
- ZCMD China
- WINT United States
- Employees
- ZCMD N/A
- WINT N/A
- Industry
- ZCMD Other Consumer Services
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZCMD Real Estate
- WINT Health Care
- Exchange
- ZCMD Nasdaq
- WINT Nasdaq
- Market Cap
- ZCMD 29.0M
- WINT 2.2M
- IPO Year
- ZCMD 2020
- WINT 1995
- Fundamental
- Price
- ZCMD $1.16
- WINT $0.73
- Analyst Decision
- ZCMD
- WINT Hold
- Analyst Count
- ZCMD 0
- WINT 1
- Target Price
- ZCMD N/A
- WINT $350.00
- AVG Volume (30 Days)
- ZCMD 597.6K
- WINT 9.9M
- Earning Date
- ZCMD 01-01-0001
- WINT 08-18-2025
- Dividend Yield
- ZCMD N/A
- WINT N/A
- EPS Growth
- ZCMD N/A
- WINT N/A
- EPS
- ZCMD N/A
- WINT N/A
- Revenue
- ZCMD $15,864,773.00
- WINT N/A
- Revenue This Year
- ZCMD N/A
- WINT N/A
- Revenue Next Year
- ZCMD N/A
- WINT N/A
- P/E Ratio
- ZCMD N/A
- WINT N/A
- Revenue Growth
- ZCMD N/A
- WINT N/A
- 52 Week Low
- ZCMD $0.95
- WINT $0.36
- 52 Week High
- ZCMD $2.97
- WINT $737.44
- Technical
- Relative Strength Index (RSI)
- ZCMD 46.90
- WINT 52.59
- Support Level
- ZCMD $1.12
- WINT $0.63
- Resistance Level
- ZCMD $1.24
- WINT $1.02
- Average True Range (ATR)
- ZCMD 0.13
- WINT 0.12
- MACD
- ZCMD -0.01
- WINT 0.03
- Stochastic Oscillator
- ZCMD 16.03
- WINT 56.06
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.